Under the agreement, Malvern, Pennsylvania-based Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to Alleviant and its clinics.
According to a news release, an initial six NeuroStar advanced therapy systems — Neuronetics’ non-drug, non-invasive treatment that can improve the quality of life for people suffering from neuro health conditions when traditional medication hasn’t helped — have been delivered in 2022.
“We are delighted to partner with Alleviant to provide more people who need it with access to NeuroStar as a new possibility for non-drug depression treatment,” Neuronetics President and CEO Keith J. Sullivan said in the release. “Alleviant’s commitment to offering innovative solutions and their focus on making the world a better place by im…